Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

We found the following factors were important for predicting the progression of glaucoma: (1) the presence of small bleeding and poor blood flow to the retina and back of the eye, (2) abnormal cell ...

AIIMS Jodhpur study shows trabeculectomy improves quality of life and lowers eye pressure in moderate–severe glaucoma, ...

Stead added that while SLT is now the first treatment that is offered to patients, a range of topical medications in the form ...

The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The ...

In a survey, nearly two-thirds of patients with glaucoma or ocular hypertension were unaware of preservative-free topical ...

A new analysis linking clinical and census data finds individual factors, rather than neighborhood conditions, are more strongly associated ...

Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing loss are all ...

Bausch + Lomb's stock remains a "Hold" despite the latest financial results. Here's what investors need to keep in mind.

The three-year initiative aims to develop two new treatments for glaucoma and myopia. Read more at straitstimes.com. Read more at straitstimes.com.

ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S.

The MarketWatch News Department was not involved in the creation of this content.-- The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sac ...